Want to see TSE:CRDL full AI Analyst Report?
CRDL Stock Chart & Stats
C$2.97
-C$0.03(-1.80%)
At close: 4:00 PM EDT
C$2.97
-C$0.03(-1.80%)
Day’s Range― - ―
52-Week RangeC$1.23 - C$3.23
Previous CloseN/A
Volume111.36K
Average Volume (3M)258.55K
Market Cap
C$196.68M
Enterprise ValueC$145.28M
Total Cash (Recent Filing)C$26.08M
Total Debt (Recent Filing)C$107.00K
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Nov 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding120,660,446
10 Day Avg. Volume178,073
30 Day Avg. Volume258,548
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$14.05Price Target Upside372.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.44
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageVery low debt limits interest obligations and reduces balance-sheet pressure while the company funds clinical development. This provides greater financial flexibility than a highly leveraged structure, although it does not eliminate the need for external capital while operations remain loss-making.
Focused Clinical PipelineA focused pipeline addressing serious cardiovascular conditions gives the company a defined development strategy and potential value-creation path. Advancing multiple anti-inflammatory and anti-fibrotic candidates may diversify clinical opportunity, though future benefits depend on trial and regulatory outcomes.
Losses Modestly ImprovedThe year-over-year reduction in net loss indicates some improvement in financial performance despite the company remaining pre-revenue. If sustained, better cost discipline could extend available funding and support development progress, although the loss level remains substantial and profitability is not yet established.
Bears Say
Pre-revenue Business ModelWith no meaningful commercial revenue, Cardiol currently lacks an operating income base to fund research and corporate costs. Its financial outcome therefore depends on clinical progress and eventual commercialization, leaving the business exposed to prolonged development timelines before recurring revenue can emerge.
Persistent Cash BurnConsistently negative operating and free cash flow means ongoing activities consume substantial cash rather than generate it. Continued development will require funding while candidates remain unapproved, increasing dependence on external capital and creating dilution or financing pressure over the next several quarters.
Shrinking Capital BaseThe material decline in equity and assets reflects the cumulative effect of ongoing losses and cash use. A smaller capital base can reduce resilience during extended clinical development, constrain flexibility in allocating resources, and increase the importance of securing additional financing.
Cardiol Therapeutics News
CRDL FAQ
What was Cardiol Therapeutics’s price range in the past 12 months?
Cardiol Therapeutics lowest stock price was C$1.23 and its highest was C$3.23 in the past 12 months.
What is Cardiol Therapeutics’s market cap?
Cardiol Therapeutics’s market cap is C$196.68M.
When is Cardiol Therapeutics’s upcoming earnings report date?
Cardiol Therapeutics’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.
How were Cardiol Therapeutics’s earnings last quarter?
Cardiol Therapeutics released its earnings results on Aug 12, 2026. The company reported -C$0.05 earnings per share for the quarter, beating the consensus estimate of -C$0.097 by C$0.047.
Is Cardiol Therapeutics overvalued?
According to Wall Street analysts Cardiol Therapeutics’s price is currently Undervalued.
Does Cardiol Therapeutics pay dividends?
Cardiol Therapeutics does not currently pay dividends.
What is Cardiol Therapeutics’s EPS estimate?
Cardiol Therapeutics’s EPS estimate is -0.09.
How many shares outstanding does Cardiol Therapeutics have?
Cardiol Therapeutics has 120,660,446 shares outstanding.
What happened to Cardiol Therapeutics’s price movement after its last earnings report?
Cardiol Therapeutics reported an EPS of -C$0.05 in its last earnings report, beating expectations of -C$0.097. Following the earnings report the stock price went up 14.151%.
Which hedge fund is a major shareholder of Cardiol Therapeutics?
Currently, no hedge funds are holding shares in TSE:CRDL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardiol Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$14.05 (372.94% Upside)
C$14.05 (372.94% Upside)
Blogger Sentiment
Neutral
TSE:CRDL Sentiment 100%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.30%
12-Months-Change
Fundamentals
Return on Equity
-180.13%
Trailing 12-Months
Asset Growth
41.62%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cardiol Therapeutics
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
CRDL Stock 12 Month Forecast
Average Price Target
C$14.05
▲(372.94% Upside)
Technical Analysis
Bausch Health Companies
―
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Medicure
―
Medexus Pharmaceuticals Inc
―